加载页面时好像出了点问题.
我们的团队已经注意到了，但如果问题仍然存在，请使用电子邮件支持小工具联系我们。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.9x - 2.1x | 2.0x |
| Historical Pb Multiple | 1.5x - 5.4x | 2.4x |
| Fair Value | 10.69$ - 11.82$ | 11.26$ |
| Upside | -6.6% - 3.2% | -1.7% |
| Benchmarks | - | Full Ticker |
| Stoke Therapeutics, Inc. | - | NasdaqGS:STOK |
| Sarepta Therapeutics, Inc. | - | NasdaqGS:SRPT |
| Alnylam Pharmaceuticals, Inc. | - | NasdaqGS:ALNY |
| Moderna, Inc. | - | NasdaqGS:MRNA |
| Biogen Inc. | - | NasdaqGS:BIIB |
| Dyne Therapeutics, Inc. | - | NasdaqGS:DYN |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| STOK | SRPT | ALNY | MRNA | BIIB | DYN | |||
| NasdaqGS:STOK | NasdaqGS:SRPT | NasdaqGS:ALNY | NasdaqGS:MRNA | NasdaqGS:BIIB | NasdaqGS:DYN | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | -22.6% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | 1.6% | NM- | ||
| Latest Twelve Months | 15.0% | 143.9% | 36.8% | 24.5% | 40.6% | -34.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -1141.1% | -70.8% | -108.6% | -89.6% | 22.6% | NA | ||
| Prior Fiscal Year | -1192.5% | -43.1% | -24.1% | -68.8% | 11.8% | NA | ||
| Latest Fiscal Year | -243.4% | 12.4% | -12.4% | -110.0% | 16.9% | NA | ||
| Latest Twelve Months | -243.4% | 12.4% | -12.4% | -110.0% | 16.9% | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -39.9% | -67.7% | -390.0% | 23.5% | 21.1% | -58.4% | ||
| Prior Fiscal Year | -60.8% | -86.2% | NM | -28.6% | 8.2% | -137.3% | ||
| Latest Twelve Months | -45.8% | 19.7% | -829.2% | -28.8% | 10.4% | -88.0% | ||
| Next Fiscal Year | -38.9% | 51.6% | 84.4% | -44.8% | 12.8% | -93.1% | ||
| Two Fiscal Years Forward | -235.0% | 47.4% | 100.0% | -58.3% | 11.5% | 113019.2% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 10.7x | 3.6x | 15.5x | 3.7x | 2.1x | NA | ||
| Price / LTM EPS | -4.4x | 29.0x | -124.9x | -3.4x | 12.4x | -4.1x | ||
| Price / Book | 1.7x | 4.5x | 518.0x | 1.1x | 1.2x | 2.1x | ||
| Price / Fwd Book | 2.5x | 2.6x | 210.6x | 1.7x | 1.1x | 5.6x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.1x | 1.7x | 518.0x | |||||
| Historical P/B Ratio | 1.5x | 2.4x | 5.4x | |||||
| Selected P/B Multiple | 1.9x | 2.0x | 2.1x | |||||
| (x) Book Value | 630 | 630 | 630 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | STOK | SRPT | ALNY | MRNA | BIIB | DYN | |
| Value of Common Equity | 390 | 6,832 | 34,754 | 12,032 | 20,254 | 1,295 | |
| (/) Shares Outstanding | 54.1 | 97.0 | 129.5 | 386.6 | 146.4 | 113.1 | |
| Implied Stock Price | 7.21 | 70.41 | 268.46 | 31.12 | 138.37 | 11.45 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 7.21 | 70.41 | 268.46 | 31.12 | 138.37 | 11.45 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |